Broderick Brian C Sells 4,833 Shares of Johnson & Johnson $JNJ

Broderick Brian C trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.3% in the second quarter, Holdings Channel reports. The fund owned 72,114 shares of the company’s stock after selling 4,833 shares during the quarter. Johnson & Johnson comprises approximately 2.2% of Broderick Brian C’s investment portfolio, making the stock its 20th biggest holding. Broderick Brian C’s holdings in Johnson & Johnson were worth $11,015,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Lakeshore Capital Group Inc. boosted its holdings in Johnson & Johnson by 20.3% during the second quarter. Lakeshore Capital Group Inc. now owns 8,743 shares of the company’s stock valued at $1,335,000 after acquiring an additional 1,475 shares during the period. REAP Financial Group LLC lifted its stake in shares of Johnson & Johnson by 28.8% in the second quarter. REAP Financial Group LLC now owns 2,176 shares of the company’s stock valued at $332,000 after buying an additional 487 shares during the period. Sax Wealth Advisors LLC lifted its stake in shares of Johnson & Johnson by 41.8% in the second quarter. Sax Wealth Advisors LLC now owns 31,320 shares of the company’s stock valued at $4,784,000 after buying an additional 9,232 shares during the period. Venturi Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 0.7% in the second quarter. Venturi Wealth Management LLC now owns 20,026 shares of the company’s stock valued at $3,059,000 after buying an additional 137 shares during the period. Finally, High Note Wealth LLC lifted its stake in shares of Johnson & Johnson by 19.5% in the second quarter. High Note Wealth LLC now owns 5,750 shares of the company’s stock valued at $878,000 after buying an additional 940 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on JNJ. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. The Goldman Sachs Group increased their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Barclays raised their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Finally, Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $191.41.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $190.97 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market cap of $459.92 billion, a P/E ratio of 20.42, a P/E/G ratio of 2.42 and a beta of 0.40. The firm has a 50 day simple moving average of $178.01 and a 200 day simple moving average of $163.56. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the business posted $2.82 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.